Key result
NOAC use linked to ~9% lower risk of incident dementia versus VKAs in AF.
Why the study?
Atrial fibrillation is associated with cognitive decline, but whether NOACs reduce the risk of dementia compared with VKAs remains unclear.
Does the use of non-vitamin K antagonist oral anticoagulants reduce the risk of new-onset dementia compared to vitamin K antagonists in patients with atrial fibrillation?
Cohort (n=237,012)
Yes
Does the use of non-vitamin K antagonist oral anticoagulants reduce the risk of new-onset dementia compared to vitamin K antagonists in patients with atrial fibrillation?
NOACs are associated with a modestly lower risk of new-onset dementia compared to VKAs in unselected patients with atrial fibrillation, further supporting their safety profile and clinical utility.
Supports NOAC preference in AF for lower dementia risk; extends mixed observational data but leaves open need for RCTs.
BACKGROUND: Atrial fibrillation (AF) is associated with cognitive decline, with anticoagulated subjects potentially having a reduced risk compared with non-anticoagulated subjects. However, whether non-vitamin K antagonist oral anticoagulants (NOACs) may reduce the risk of dementia compared with vitamin K antagonists (VKAs) is unclear yet. Therefore, the risk of dementia was compared between AF subjects on NOACs versus VKAs. METHODS: AF subjects initiating anticoagulation between 2013 and 2019 were identified in Belgian nationwide data. Inverse probability of treatment weighted Cox regression was used to investigate cognitive outcomes. RESULTS: Among 237,012 AF subjects (310,850 person-years (PYs)), NOAC use was associated with a significantly lower risk of dementia (adjusted hazard ratio (aHR) 0.91, 95% confidence interval (CI) (0.85-0.98)) compared with VKAs. A trend towards a lower risk of vascular dementia (aHR 0.89, 95% CI (0.76-1.04)) and significantly lower risk of other/unspecified dementia (aHR 0.91, 95% CI (0.84-0.99)) were observed with NOACs compared with VKAs, whereas the risk of Alzheimer's disease was similar (aHR 0.99, 95% CI (0.88-1.11)). Apixaban (aHR 0.91, 95% CI (0.83-0.99)) and edoxaban (aHR 0.79, 95% CI (0.63-0.99)) were associated with significantly lower risks of dementia compared with VKAs, while risks were not significantly different with dabigatran (aHR 1.02, 95% CI (0.93-1.12)) and rivaroxaban (aHR 0.97, 95% CI (0.90-1.05)). Comparable risks of dementia were observed between individual NOACs, except for significantly lower risks of dementia (aHR 0.93, 95% CI (0.87-0.98)) and other/unspecified dementia (aHR 0.90 (0.84-0.97)) with apixaban compared with rivaroxaban. CONCLUSION: NOACs were associated with a significantly lower risk of dementia compared with VKAs, likely driven by apixaban and edoxaban use.
No takes yet. Share an insight, caveat, or question.
Grymonprez et al. (2023) conducted a cohort in Atrial Fibrillation (n=237,012). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated on New-onset dementia (aHR 0.91, 95% CI 0.85-0.98). NOAC use was associated with a 9% significantly lower risk of new-onset dementia (aHR 0.91) compared with VKAs in unselected subjects with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: